May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Immunohistochemical Localization of Integrins in Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • A.L. Ning
    Ophthalmology and Visual Sciences, Univ of British Columbia, Vancouver, BC, Canada
  • J. Cui
    Ophthalmology and Visual Sciences, Univ of British Columbia, Vancouver, BC, Canada
  • J.A. Matsubara
    Ophthalmology and Visual Sciences, Univ of British Columbia, Vancouver, BC, Canada
  • Footnotes
    Commercial Relationships  A.L. Ning, None; J. Cui, None; J.A. Matsubara, None.
  • Footnotes
    Support  CIHR MOP 42389
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 383. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.L. Ning, J. Cui, J.A. Matsubara; Immunohistochemical Localization of Integrins in Proliferative Diabetic Retinopathy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):383.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Integrins are a class of heterodimeric plasma membrane proteins that play an important role in cell–extracellular matrix and/or cell–cell interactions. Recently, integrins have been shown to play a role in the pathogenesis of a variety of proliferative diseases including angiogenesis. The integrins implicated in an angiogenic response include α1 ß1, α2 ß1, α5 ß1, αV ß3, ß3 and αV ß5. The purpose of the study is to investigate the expression and co–localization of integrins and endothelial cells in various stages of proliferative diabetic retinopathy (PDR). Methods: Eight PDR membranes were collected from eyes via vitreoretinal surgery. A double immunohistochemical staining procedure was used to identify the presence and co–localization of integrins and endothelial cells. Primary antibodies against α1 ß1, α2 ß1, α5 ß1, αV ß3, ß3 and αV ß5 were used in combination with primary antibodies against Von Willibrand Factor (VWF) or CD31, both markers of endothelial cells. Secondary antibodies were tagged with Alexa–488 or Cy3. The Zeiss Inverted Axiovert 200M Confocal Laser–scanning Microscope (Zeiss–LSM 510 META) was used to visualize immunohistochemical labeling. Tonsil tissues were used as positive control tissue in this study. Results: Cells in PDR membranes expressed α1 ß1, α2 ß1, αV ß3, and ß3, but not α5 ß1 or αV ß5. Of the four that are expressed in PDR membranes, only two, αV ß3 and ß3, demonstrated colocalization with endothelial cells. Late stage PDR membranes, characterized by fibrosis, were negative for both integrins and endothelial cells. Conclusions: PDR membranes are positive for α1 ß1, α2 ß1, αV ß3 and ß3 integrins. Of these, only αV ß3 and ß3 colocalize with endothelial cells within PDR membranes. These results suggest that therapeutic applications focused on blocking α V ß3 and/or ß3 may be helpful in minimizing neovascularization in proliferative diabetic retinopathy.

Keywords: diabetic retinopathy • growth factors/growth factor receptors • immunohistochemistry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×